DHA-clozapine

DHA-clozapine (tentative trade name Clozaprexin)[1] is an atypical antipsychotic drug candidate that was created and originally tested by chemists at Protarga, a small pharmaceutical in Pennsylvania, and scientists at Harvard University.[2]

DHA-clozapine
Clinical data
Trade namesClozaprexin
Other namesDocosahexaenoyl clozapine
ATC code
  • none
Legal status
Legal status
Identifiers
CAS Number
PubChem CID
ChemSpider
Chemical and physical data
FormulaC40H49ClN4O
Molar mass637.30 g/mol g·mol−1
3D model (JSmol)
 NY (what is this?)  (verify)

It is a prodrug of clozapine; the fatty acid docosahexaenoic acid (DHA) was added to clozapine in order to increase penetration of the blood–brain barrier.[3]

Protarga was purchased by Luitpold Pharmaceuticals in 2003 and development was discontinued in 2007.[1]


References
  1. "DHA-clozapine". AdisInsight. Retrieved 17 March 2017.
  2. Rosack, Jim (4 May 2001). "Targaceuticals Point Way To Developing Safer Drugs". Psychiatric News. doi:10.1176/pn.36.9.0036.
  3. Baldessarini, R.; Campbell, A.; Webb, N. L.; Swindell, C. S.; Flood, J. G.; Shashoua, V. E.; Kula, N. S.; Hemamalini, S; Bradley, M. O (200). "Fatty Acid Derivatives of Clozapine Prolonged Antidopaminergic Activity of Docosahexaenoylclozapine in the Rat". Neuropsychopharmacology. 2 (1): 55–65. doi:10.1016/S0893-133X(00)00173-1. PMID 11106876.



This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.